

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

Wednesday, January 14, 2026 – 12:00 PM – 1:30 PM

- Present:** Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Venkateswara Davuluri,
Dr. John Shand
- Absent:** Dr. Craig Butler, Dr. Kolin Good (voted), Dr. Chris Squillaro, Grace Robinson (CHC Participant)
- Non-Voting Members:** Amy Nowacki (Pharmacy), Rhonda Montesano (Pharmacy), Shalyn Kline (Pharmacy), Tanayja Sams (Pharmacy),
George Kimbrow (Clinical Policy Coordinator), Heather Clarke (Director of Case Management).
- Call to Order:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:04 PM.
- Adjourned:** The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:26 PM.
- Next Meeting:** Wednesday, April 8, 2026 – 12:00 PM
- Submitted By:** Shalyn Kline (PHW Pharmacy)

Committee Chair: Shalyn Kline

Date: 04/08/2026

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Jason called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:04 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	No new introductions			Jason Skaria
B. Announcements	Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	<ul style="list-style-type: none"> i. Voting and vote totals ii. Tie breaker iii. Pennsylvania's Review and Approval Process 	No action required or taken.		Jason Skaria
D. Charter Review	The committee charter was reviewed with the committee members.	No action required or taken.		Jason Skaria
II. Approval of Meeting Minutes	<p>A vote was taken for the approval of the minutes from Q4_2025. No objections were made.</p> <p>Motion to approve: Jill Schaeffer Second motion to approve: Dr. John Shand</p>	Adoption of Q4_2025 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business	No old business	No action required or taken.		Shalyn Kline
A. Policy Submission Status	There are 49 outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
IV. New Business				

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

<p>A. Provider Education</p>	<p>A vote was taken for the approval of the Pain Management in Sickle Cell Anemia provider education. No objections were made.</p> <p>Motion to approve: Michelle Bennett Second motion to approve: Jill Schaeffer</p>	<p>The provider education was Committee approved.</p>		<p>Shalyn Kline</p>
<p>B. FDA Updates</p>	<p>This is informational only and addresses recalls, new drugs, etc. No vote necessary.</p>	<p>Informational</p>		<p>Shalyn Kline</p>
<p>C. Guidelines – Drug Coverage Criteria</p>	<p>Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 7 new policies created, 47 policies had clinically significant change, 48 policies with no significant changes and 2 policies being replaced/retired for Medicaid. No objections, concerns or comments were made.</p> <p>Motion to approve: Dr. John Shand Second motion to approve: Michelle Bennett</p> <p>A vote was taken for the approval of 3 new policies created, 120 policies had clinically significant change, 69 policies with no significant changes and 2 policies being replaced/retired for CHIP. No objections, concerns or comments were made.</p> <p>Motion to approve: Jill Schaeffer Second motion to approve: Dr. John Shand</p>	<p>The policy revisions were Committee approved.</p>		<p>Shalyn Kline</p>
<p>D. Additional Drug Lists and Policies and Procedures</p>	<p>A vote was taken for the approval of the Supplemental Drug List, 3 Pharmacy Policy & Procedures and Quantity Limit List</p> <p>Motion to approve: Jill Schaeffer Second motion to approve: Michelle Bennett</p>	<p>The policy and drug lists revisions were Committee approved.</p>		<p>Shalyn Kline</p>
<p>E. Highlights of New Medications/ Significant Changes</p>	<p>Shalyn reviewed as of 1/1/2026, GLP-1 receptor agonists are no longer covered for overweight and obesity and GLP-1 receptor agonist will now be reviewed with GLP-1 receptor agonist policy.</p>	<p>No action required or taken.</p>		<p>Shalyn Kline</p>

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	<p>As of 1/5/2026, Journavx moved to the Statewide PDL and will be reviewed with the new policy: Analgesics, Acute Pain Agents. Shalyn reviewed oral Wegovy, it is indicated for Major Adverse Cardiovascular Events (MACE) and overweight/obesity, predicted to cost less than the injectable Wegovy. Oral Wegovy is not indicated for anyone under 18 years old and Metabolic dysfunction-Associated Steatohepatitis (MASH). Shalyn reviewed oral Wegovy dosing. Dr. Shand asked about the how many members were impacted by the ending of coverage of obesity and overweight. Jason responded that there were about 450 members impacted by the ending of coverage.</p>			
<p>F. Complaints and Grievances Review</p>	<p>Shalyn stated that there was 2 determinations upheld and 2 overturned and 0 withdrawn during pre-grievance. 0 of the 4 determinations were for opioids. Two of the 4 determinations were for GLP-1 receptor agonists.</p>	<p>No action required or taken.</p>		<p>Shalyn Kline</p>
<p>G. Drug Utilization Review</p>	<p>Shalyn presented the drug utilization review for Q4 2025, there were almost 10,000 DUR provider outreaches and only 520 were resolved.</p> <p>FWA – There were 90 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. 50 participants were identified for provider outreach. 1 participant was identified with three or more practices/hospitals prescribing opioids.</p>	<p>No action required or taken.</p>		<p>Shalyn Kline</p>
<p>H. PBM Oversight</p>	<p>Prior Authorization Audits:</p> <ul style="list-style-type: none"> • October – 98.44% pass rate • November – 96.91% pass rate • December – 93.44% pass rate <p>Call Center: service levels met</p> <ul style="list-style-type: none"> • Average Q4 2025- 99.81 % <p>Dr. Shand asked about what could lead to a failed audit. Jason stated it could be the readability of a letter or mismatch provider/member letter.</p>	<p>No action required or taken.</p>		<p>Jason Skaria</p>

CONFIDENTIAL

Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

K. Open Forum	Evan has moved on to a supervisor roll with our New York plan and we will be hiring a new pharmacist, hopefully before the next quarter.	No action required or taken.		Jason Skaria
Adjournment	<p>The meeting was adjourned at 12:25 pm</p> <p>Jason asked for a motion to adjourn.</p> <p>Motion to adjourn: Dr. John Shand</p> <p>Second motion to adjourn: Jill Schaeffer</p>	Meeting adjourned		Jason Skaria

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S.ξ1137 (b)).